Playback speed
10 seconds
ASCO 2022 on Randomized Phase II Trial of Neoadjuvant ADT + Abiraterone & Apalutamide for High-Risk Localized Prostate Cancer: Pathologic Response and PSMA Imaging Correlates
By
ASCO 2022 Conference Coverage
FEATURING
Diogo Bastos
By
ASCO 2022 Conference Coverage
FEATURING
Diogo Bastos
0 views
June 9, 2022
Comments 0
Login to view comments.
Click here to Login